Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
June 04 2013 - 8:00AM
Marketwired
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company
focused on the research, development and commercialization of drugs
for the treatment of various forms of cancer, today announced that
it has completed a new IND-Enabling study in which Adva-27a, the
Company's flagship oncology drug candidate for breast cancer was
found to be effective at killing Pancreatic Cancer Cells in vitro.
The study was carried out in the well-established very aggressive
Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill
these cells with an IC50 of less than 4 micromolar, a
pharmacologically very favorable drug concentration. Sunshine
Biopharma had previously reported that Adva-27a is capable of
effectively killing other aggressive or multidrug resistant cancer
cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung
Cancer cells (H69AR), and Uterine Sarcoma cells (MES-SA/Dx5).
"This brings to four the total number of Aggressive or Multidrug
Resistant Cancer types that Adva-27a can destroy. Other
chemotherapy drugs are completely ineffective against these
cancers," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.
"This confirms the general effectiveness of Adva-27a against
Aggressive or Multidrug Resistant Cancer," he added.
About Pancreatic Cancer Pancreatic cancer
has an extremely poor prognosis. Most pancreatic cancer patients
will die within one year of diagnosis. Cancer of the pancreas is
the fourth most common cause of cancer-related deaths in the United
States. According to the American Cancer Society, an estimated
45,220 new cases of pancreatic cancer will be diagnosed in the U.S.
in 2013. Approximately 95% of pancreatic tumors are of the
adenocarcinoma type, arising within the exocrine component of the
pancreas where various digestive enzymes are produced. The
remaining 5% arise from the islet cells and are classified as
neuroendocrine tumors. The islet cells produce important hormones
such as insulin, which regulates the sugar levels in the blood.
Both types are very aggressive and respond poorly to standard
chemotherapy drugs. In contrast to the downward trend in death
rates for most major cancer types, such as lung, colorectal, female
breast and prostate, death rates due to pancreatic cancer have been
slowly increasing in the U.S. over the past decade. This, together
with the lack effective therapy, underscores the need for major new
drug development efforts to reverse these trends.
About Sunshine Biopharma Inc. Sunshine
Biopharma is an early stage pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of various forms of cancer. Sunshine Biopharma recently
announced that it has initiated IND-Enabling studies for its lead
antitumor compound, Adva-27a, which is currently targeted for
multidrug resistant cancer.
Safe Harbor Forward-Looking Statements To
the extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's development,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO
Sunshine Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com